{ "kind": "all", "value": "all", "collectionKey": "slides:all:all:all-document-kinds:all-producers:all-orientations", "filters": { "documentKinds": [], "sourceTypes": [], "orientations": [] }, "total": 319975, "page": 2254, "pageSize": 60, "pageCount": 5333, "rows": [ { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 57, "slideType": "other", "function": "present_framework", "notes": "The diagram uses a central triangle to represent the entity, with arrows indicating capital inflows from IPO, private phase rollovers, and management investments.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/57", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-57", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 58, "slideType": "kpi_overview", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/58", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-58", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 59, "slideType": "valuation_table", "function": "analyze_data", "notes": "The slide provides a snapshot of the discount to NAV for PSH, including specific historical high/low/average discount data.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/59", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-59", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 60, "slideType": "peer_gap", "function": "expose_gap", "notes": "The chart shows the stock price (blue) consistently trading below the NAV (green).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/60", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-60", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 61, "slideType": "key_takeaways", "function": "analyze_data", "notes": "The chart highlights a significant disparity between broker-traded and exchange-traded volumes, with a dashed line indicating the weekly average.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/61", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-61", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 62, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide highlights that broker trading volume is 2.2x exchange traded volume.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/62", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-62", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 63, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/63", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-63", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 64, "slideType": "team_bio", "function": "introduce_nominees", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/64", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-64", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 65, "slideType": "team_bio", "function": "introduce_nominees", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/65", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-65", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 66, "slideType": "transition", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/66", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-66", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-905be5d022fb", "docSlug": "0c95c1ec255f", "documentTitle": "Pershing Square Portfolio (multiple positions)", "authorId": "01_Pershing_Square", "authorName": "Pershing Square", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-04-28 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 67, "slideType": "appendix_disclosure", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-905be5d022fb/67", "deckHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-905be5d022fb#slide-67", "loopMatches": [], "arcBeatMatches": [ { "to": 67, "from": 51, "beatId": "6a6a2a0f-f7e4-4d65-94a2-ee903bbb1ddb", "arcName": "Rags to Riches", "arcSlug": "rags-to-riches", "beatName": "Ultimate Achievement", "beatSlug": "rags-to-riches-ultimate-achievement", "evidence": "Summary of investment results and future outlook.", "position": 4, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 1, "slideType": "other", "function": "other", "notes": "Minimalist slide with a single metric and company branding.", "imagePath": "https://imgproxy.kitesheet.com/LgriFBeWr7JyWCT0FtYHbvOh1v8PiizvccgRKQWv08Y/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMDI3NzRmNjc2OTQvcDAwMS5qcGc", "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/1", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-1", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": "https://imgproxy.kitesheet.com/mGhRsdc8gSAnLksXshiZmaxxtxraXTu1FGml9cPPf9o/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMDI3NzRmNjc2OTQvcDAwMS5wbmc", "thumbSrc": "https://imgproxy.kitesheet.com/vZcTDF_3MqWRSwDt5xOvPE11zMQqY8QTnq9OnP2GWfE/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMDI3NzRmNjc2OTQvcDAwMS5qcGc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/9HIZeNAv_S2wiqtsCRfuX0vVJ4GDL3J94KvzDwqnkgg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy8wMDI3NzRmNjc2OTQvcDAwMS5wbmc" }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 2, "slideType": "disclaimer", "function": "other", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/2", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-2", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 3, "slideType": "other", "function": "illustrate_case", "notes": "The chart uses a timeline-based annotation style to correlate M&A activity with stock performance.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/3", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-3", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 4, "slideType": "valuation_reveal", "function": "show_valuation_bridge", "notes": "The chart demonstrates long-term market mispricing of earnings growth potential.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/4", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-4", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 5, "slideType": "other", "function": "establish_context", "notes": "This slide provides a high-level company profile and performance summary.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/5", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-5", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 6, "slideType": "before_after", "function": "illustrate_case", "notes": "The chart uses callout boxes to correlate specific acquisition announcements with share price movements.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/6", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-6", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 7, "slideType": "key_messages", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/7", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-7", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 8, "slideType": "before_after", "function": "illustrate_case", "notes": "The chart uses callouts to annotate specific events (IPO and acquisition announcement) that correlate with share price movements.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/8", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-8", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 9, "slideType": "problem_statement", "function": "diagnose_problem", "notes": "Uses a diagnostic structure to debunk potential explanations for stock performance.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/9", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-9", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 9, "beatId": "738bca32-100f-46cb-b5a8-abd6f3015dc3", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "Nomad Holdings: Why Has the Stock Gone Up So Much?", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 10, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/10", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-10", "loopMatches": [], "arcBeatMatches": [ { "to": 10, "from": 9, "beatId": "738bca32-100f-46cb-b5a8-abd6f3015dc3", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Problem", "beatSlug": "problem-agitate-solution-problem-identify-pain", "evidence": "Nomad Holdings: Why Has the Stock Gone Up So Much?", "position": 0, "confidence": 0.8, "parentBeatName": "Complication", "parentBeatSlug": "complication" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 11, "slideType": "thesis_headline", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/11", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-11", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 12, "slideType": "key_messages", "function": "present_framework", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/12", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-12", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 13, "slideType": "thesis_headline", "function": "diagnose_problem", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/13", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-13", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 14, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/14", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-14", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 15, "slideType": "key_takeaways", "function": "summarize", "notes": "The chart uses a 4,502% return figure to illustrate the ~45x growth mentioned in the action title.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/15", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-15", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 16, "slideType": "key_messages", "function": "present_framework", "notes": "This slide outlines the core 'roll-up' strategy that defined Valeant's business model.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/16", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-16", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 17, "slideType": "key_takeaways", "function": "summarize", "notes": "The slide outlines the core pillars of Valeant's M&A success.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/17", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-17", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 18, "slideType": "valuation_table", "function": "present_framework", "notes": "Uses a qualitative scoring system represented by filled/partially filled circles.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/18", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-18", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 19, "slideType": "other", "function": "establish_context", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/19", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-19", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 20, "slideType": "valuation_table", "function": "quantify_opportunity", "notes": "The table uses a low/mid/high scenario approach to calculate value creation based on multiples of 2014 Pro-Forma Free Cash Flow.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/20", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-20", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" }, { "to": 21, "from": 20, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "12706e38-8446-440f-92cf-59ac5deba902", "evidence": "Clear before-and-after comparison", "position": 1, "objective": "Show Valeant stock price increase after Bausch & Lomb transaction", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.8, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 21, "slideType": "before_after", "function": "analyze_data", "notes": "The slide uses callout boxes to correlate specific corporate events with stock price movements.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/21", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-21", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" }, { "to": 21, "from": 20, "name": "Before After", "slug": "21-before-after", "bestFor": "Product demos, process improvements, ROI justification", "matchId": "12706e38-8446-440f-92cf-59ac5deba902", "evidence": "Clear before-and-after comparison", "position": 1, "objective": "Show Valeant stock price increase after Bausch & Lomb transaction", "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta", "confidence": 0.8, "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 22, "slideType": "thesis_headline", "function": "analyze_data", "notes": "The chart illustrates the 'multiple expansion' of Valeant's stock relative to a fixed future earnings consensus.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/22", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-22", "loopMatches": [ { "to": 22, "from": 11, "name": "Logic Chain", "slug": "01-logic-chain", "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis", "matchId": "a77fe409-3012-4f62-bf20-94f87bf56e5f", "evidence": "Clear logic chain from platform strategy to shareholder value", "position": 0, "objective": "Understand Valeant's platform strategy and value creation", "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)", "confidence": 0.7, "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion" } ], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 23, "slideType": "problem_statement", "function": "frame_problem", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/23", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-23", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 23, "beatId": "99e25aef-066a-4db9-83ff-068988eafc48", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "Why the Stock Market Undervalues Platform Companies", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 24, "slideType": "testimonial", "function": "cite_precedent", "notes": "The slide uses a torn-paper aesthetic for the quotes.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/24", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-24", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 23, "beatId": "99e25aef-066a-4db9-83ff-068988eafc48", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "Why the Stock Market Undervalues Platform Companies", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 25, "slideType": "section_divider", "function": "transition", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/25", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-25", "loopMatches": [], "arcBeatMatches": [ { "to": 25, "from": 23, "beatId": "99e25aef-066a-4db9-83ff-068988eafc48", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Agitate", "beatSlug": "problem-agitate-solution-agitate-make-it-worse", "evidence": "Why the Stock Market Undervalues Platform Companies", "position": 1, "confidence": 0.8, "parentBeatName": "Development", "parentBeatSlug": "development" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 26, "slideType": "valuation_reveal", "function": "show_valuation_bridge", "notes": "The slide uses a 'However' transition to pivot from a standard valuation to a more complex, asset-based argument.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/26", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-26", "loopMatches": [], "arcBeatMatches": [ { "to": 30, "from": 26, "beatId": "b3192691-5948-440e-9c72-ce287a2df51f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "Valeant Valuation Model and Summary", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 27, "slideType": "valuation_table", "function": "analyze_data", "notes": "The slide uses a structured table format to justify valuation inputs for an acquisition model.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/27", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-27", "loopMatches": [], "arcBeatMatches": [ { "to": 30, "from": 26, "beatId": "b3192691-5948-440e-9c72-ce287a2df51f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "Valeant Valuation Model and Summary", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 28, "slideType": "scenario_table", "function": "analyze_data", "notes": "The table models four scenarios based on annual M&A spend ($0bn, $5bn, $10bn, $20bn).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/28", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-28", "loopMatches": [], "arcBeatMatches": [ { "to": 30, "from": 26, "beatId": "b3192691-5948-440e-9c72-ce287a2df51f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "Valeant Valuation Model and Summary", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 29, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": "The table uses a weighted average approach (70% * 20.0x + 30% * 8.0x = 16.4x).", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/29", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-29", "loopMatches": [], "arcBeatMatches": [ { "to": 30, "from": 26, "beatId": "b3192691-5948-440e-9c72-ce287a2df51f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "Valeant Valuation Model and Summary", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 30, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": "The slide uses a 10% discount rate for PV calculations and assumes a constant 16x NTM P/E multiple.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/30", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-30", "loopMatches": [], "arcBeatMatches": [ { "to": 30, "from": 26, "beatId": "b3192691-5948-440e-9c72-ce287a2df51f", "arcName": "Problem-Agitate-Solution", "arcSlug": "problem-agitate-solution", "beatName": "Solution", "beatSlug": "problem-agitate-solution-solution-provide-relief", "evidence": "Valeant Valuation Model and Summary", "position": 2, "confidence": 0.8, "parentBeatName": "Resolution", "parentBeatSlug": "resolution" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 31, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": "Includes disclaimer regarding valuation assumptions and data sources.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/31", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-31", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 32, "slideType": "executive_summary", "function": "summarize", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/32", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-32", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 33, "slideType": "appendix", "function": "appendix", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/33", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-33", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 34, "slideType": "comparison_table", "function": "frame_situation", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/34", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-34", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 35, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/35", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-35", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 36, "slideType": "peer_gap", "function": "expose_gap", "notes": "Uses 'X' icons to denote negative attributes of peer groups.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/36", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-36", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 37, "slideType": "peer_benchmark", "function": "compare_peers", "notes": "The slide uses specific financial metrics (EBITA, Gross Margin, Forward EPS) to establish a peer benchmark for Valeant's portfolio durability.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/37", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-37", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 38, "slideType": "precedent_table", "function": "cite_precedent", "notes": "The table includes a calculated average row at the bottom.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/38", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-38", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 39, "slideType": "comparison_table", "function": "compare_peers", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/39", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-39", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 40, "slideType": "comparison_table", "function": "compare_peers", "notes": "The slide justifies using non-healthcare benchmarks for valuation by highlighting similar margin and growth profiles.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/40", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-40", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 41, "slideType": "valuation_table", "function": "compare_peers", "notes": "The slide uses a bar chart to establish a valuation benchmark for non-healthcare sectors.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/41", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-41", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 42, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": "The chart uses a box-plot style to show ranges for different comparable categories.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/42", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-42", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 43, "slideType": "valuation_table", "function": "analyze_data", "notes": null, "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/43", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-43", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 44, "slideType": "valuation_table", "function": "show_valuation_bridge", "notes": "The slide uses a bridge framework to reconcile 2015 revenue to 2020 estimates for cliff products.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/44", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-44", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 45, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide provides specific financial modeling parameters for Valeant and Salix, excluding future acquisitions.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/45", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-45", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 46, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide details specific financial ratios (90% conversion, 4x leverage target, 5.75% cost of debt) and compares them to current/transaction-specific metrics.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/46", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-46", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-9646c0061f4f", "docSlug": "002774f67694", "documentTitle": "Valeant Pharmaceuticals International (VRX)", "authorId": "01_Pershing_Square", "authorName": "William Ackman", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-05-04 00:00:00", "orientation": "portrait", "aspectRatio": 0.77272725, "pageNumber": 47, "slideType": "appendix_data", "function": "analyze_data", "notes": "The slide details the logic for M&A spending caps and the subsequent use of excess debt capacity for share repurchases.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-9646c0061f4f/47", "deckHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-9646c0061f4f#slide-47", "loopMatches": [], "arcBeatMatches": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }, { "docId": "019dd923-622c-750b-8b9b-981a4fc19659", "docSlug": "7028d690f66f", "documentTitle": "Herbalife, Ltd. (HLF)", "authorId": "01_Pershing_Square", "authorName": "David Klafter", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-06-26 00:00:00", "orientation": "portrait", "aspectRatio": 0.7739104, "pageNumber": 1, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "This is a formal letter formatted as a slide.", "imagePath": "https://imgproxy.kitesheet.com/woE1asxe8AG2dDT5LDFs9c_1xq3beCDOa3uZzMkMJ5c/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83MDI4ZDY5MGY2NmYvcDAwMS5wbmc", "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-981a4fc19659/1", "deckHref": "/decks/019dd923-622c-750b-8b9b-981a4fc19659", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-981a4fc19659#slide-1", "loopMatches": [], "arcBeatMatches": [ { "to": 1, "from": 1, "beatId": "d2e0485b-7eb1-4f9c-9089-d363a7cae205", "arcName": "Overcoming the Monster", "arcSlug": "overcoming-monster", "beatName": "Hook", "beatSlug": "hook", "evidence": "The letter begins with a direct address to Mr. Johnson, grabbing his attention.", "position": 0, "confidence": 0.6, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": "https://imgproxy.kitesheet.com/XfOcCVZAk5YCuygxP6mOdJP4RCisTc-dPrris5xpeAE/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83MDI4ZDY5MGY2NmYvcDAwMS5qcGc", "thumbSrc": "https://imgproxy.kitesheet.com/X4H9ishQ-RFqpD8Zc9jPUQqneqndpvrnsf_9Co-ybT4/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83MDI4ZDY5MGY2NmYvcDAwMS5wbmc", "thumbSrcAlt": "https://imgproxy.kitesheet.com/pHZQnQyxj53D6owEAFxy6cVS5LFnnpHkTYVHNLl8acg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83MDI4ZDY5MGY2NmYvcDAwMS5qcGc" }, { "docId": "019dd923-622c-750b-8b9b-981a4fc19659", "docSlug": "7028d690f66f", "documentTitle": "Herbalife, Ltd. (HLF)", "authorId": "01_Pershing_Square", "authorName": "David Klafter", "documentKindSlug": "shareholder-letter", "documentKindLabel": "Shareholder letter", "sourceTypeSlug": "activist_investor", "sourceTypeLabel": "Activist investor", "presentationDate": "2015-06-26 00:00:00", "orientation": "portrait", "aspectRatio": 0.7739104, "pageNumber": 2, "slideType": "expose_contradiction", "function": "expose_contradiction", "notes": "This is a formal letter/document page, not a typical presentation slide.", "imagePath": null, "matchCount": 1, "evidence": null, "slideHref": "/slides/019dd923-622c-750b-8b9b-981a4fc19659/2", "deckHref": "/decks/019dd923-622c-750b-8b9b-981a4fc19659", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-981a4fc19659#slide-2", "loopMatches": [], "arcBeatMatches": [ { "to": 2, "from": 2, "beatId": "2c4b935b-4a24-4828-9070-78dfeed0700a", "arcName": "Overcoming the Monster", "arcSlug": "overcoming-monster", "beatName": "Complication", "beatSlug": "complication", "evidence": "The mention of a contradiction and the involvement of Herbalife and its top recruiters introduces a complication.", "position": 1, "confidence": 0.6, "parentBeatName": null, "parentBeatSlug": null } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true } ] }